Journal of the Neurological Sciences
Volume 203 , Pages 131-136 , 15 November 2002

The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease

  • C Grantham

      Affiliations

    • Corresponding Author InformationCorresponding author. Present address: Johnsons&Johnson Pharmaceutical Research & Development, Beerse, Belgium. Tel.: +32-14-60-63-09; fax: +32-14-60-61-11.
    • Janssen Research Foundation, Turhoutseweg 30, B-2340 Beerse, Belgium
    • ,
  • H Geerts

      Affiliations

    • In Silico Biosciences, Philadelphia, PA, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0022-510X(02)00274-5

Journal of the Neurological Sciences
Volume 203 , Pages 131-136 , 15 November 2002

Article Tools

* Image Usage & Resolution